Research suggests that the medication, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, originally developed to manage Type 2 diabetes, may be able to treat a wide range of conditions involving impulse control, like binge eating disorder.But although there may be tantalizing clues for helping patients with unwanted impulses, GLP-1 and GIP inhibitors may not be optimally designed to treat them sufficiently and need further research, according to a case study from the Perelman School of Medicine at the University of Pennsylvania, published today in Nature Medicine
A new gastric juice peptide, BPC: an overview of the stomach-stress-organoprotection hypothesis
Intranasal delivery bypasses this and provides partial direct nose-to-brain transport through olfactory and trigeminal pathways, alongside systemic absorption across the respiratory mucosa
Moreover, it has anti-inflammatory properties, which can help keep the skin calm and clear
10.1016/j.redox.2023.102826 33 DingC.HeR.ZhangJ.DongZ.WuJ
Strategies to improve sleep (eg, targeting 78 hours per night) may improve male fertility markers
